Catalent, Inc. (CTLT)
NYSE: CTLT · IEX Real-Time Price · USD
57.91
-0.08 (-0.14%)
At close: Jul 19, 2024, 4:00 PM
57.77
-0.14 (-0.24%)
Pre-market: Jul 22, 2024, 6:12 AM EDT
Catalent Employees
Catalent had 17,800 employees as of June 30, 2023. The number of employees decreased by 1,200 or -6.32% compared to the previous year.
Employees
17,800
Change (1Y)
-1,200
Growth (1Y)
-6.32%
Revenue / Employee
$232,303
Profits / Employee
-$66,067
Market Cap
10.48B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 17,800 | -1,200 | -6.32% |
Jun 30, 2022 | 19,000 | 1,700 | 9.83% |
Jun 30, 2021 | 17,300 | 3,400 | 24.46% |
Jun 30, 2020 | 13,900 | 1,600 | 13.01% |
Jun 30, 2019 | 12,300 | 1,600 | 14.95% |
Jun 30, 2018 | 10,700 | -100 | -0.93% |
Jun 30, 2017 | 10,800 | 1,600 | 17.39% |
Jun 30, 2016 | 9,200 | 500 | 5.75% |
Jun 30, 2015 | 8,700 | 400 | 4.82% |
Jun 30, 2014 | 8,300 | 0 | - |
Sep 30, 2013 | 8,300 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Walgreens Boots Alliance | 331,000 |
Fresenius Medical Care AG & Co. KGaA | 119,845 |
Universal Health Services | 96,700 |
Charles River Laboratories International | 21,800 |
Solventum | 20,098 |
Teleflex | 14,500 |
AptarGroup | 13,800 |
Globus Medical | 5,000 |
CTLT News
- 6 days ago - Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany - Business Wire
- 4 weeks ago - Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty - Benzinga
- 7 weeks ago - Catalent stockholders approve deal with Novo Holdings - Reuters
- 7 weeks ago - Catalent Stockholders Approve Transaction with Novo Holdings - Business Wire
- 7 weeks ago - Surely Wines Appoints Brandon Joldersma as New CEO - Business Wire
- 2 months ago - Catalent, Inc. Reports Third Quarter Fiscal 2024 Results - Business Wire
- 2 months ago - Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer - GlobeNewsWire
- 2 months ago - FTC Seeks More Information on $16.5 Billion Novo-Catalent Deal - WSJ